ring

Dade Behrings (hsCRP) Tests and BNTM Series Analyzers

C-Reactive Protein (CRP) is an inflammatory marker that has been associated with an increased risk of having a cardiovascular eventeven in the face of normal LDL levelsin several studies. CRP is created by the liver during systemic infection, and is an acute inflammatory marker. While CRP testing has been around for many years, it has only been recently that tests sensitive enough to measure...

Monitoring Patient Glucose Levels: New Advances in software make it easier

Monitoring patient glucose levels and determining the response to intervention is critical when working with diabetic clients. The benefit of doing so in improved outcomes for both type 1 and type 2 diabetes has been clearly established by clinical trials conducted in both the U.S. and the UK1. Self- monitoring by patients of glucose levels, and the data provided is especially important for p...

Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse

In keeping with the recent proliferation of rapid, easy-to-use diagnostic tests, many assays and collection products have entered the marketplace to help clinicians assess dosage appropriateness of therapeutic drugs and to screen for the presence of drugs of abuse. Some of these products require laboratory support while many simple test kits are suitable for point of care use by medical profe...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Biotec Pharmacon Announces Preliminary Results from the Sloan-Kettering Clinical Study

TROMSØ, Norway, June 29, 2007-Preliminary results fromthe immunotherapeutic cancer study at Memorial Sloan-KetteringCancer Center show a very good safety profile for SBG. Furthermore,encouraging responses on cancer development have been observedamong several patients that have been treated with SBG incombination with the monoclonal antibody against neuroblastoma. In line wit...

Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, anemerging pharmaceutical company specialized in ophthalmologypresents positive results of its pivotal phase III clinical trialpositive results from the Phase III clinical study of Vekacia(R) inchildren suffering from Vernal Keratoconjunctivitis (VKC) at theXIV Afro-Asian Congress of ophthalmology (AACO) held from June 20to 25...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

New study demonstrates 75% of patients receiving highest doseachieves A1c with no associated hypoglycemia CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- According tofindings presented today at the 67th Scientific Sessions of theAmerican Diabetes Association (ADA) in Chicago, Illinois, theinvestigational treatment liraglutide, a once- daily dose of humanGLP-1 analog under development by...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25/ - 13 mm Hg (systolic / diastolic, p - Blood pressure reduction dependent on vaccine dose and inducedantiangiotensin II antibody levels - Detailed results presented today at the Seventeenth EuropeanMeeting on Hypertension in Milan, Italy SCHLIEREN (Zurich), Switzerland and MILAN, Ita...

Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England

"The editorials published by the NEJM are disappointing andmisleading in that they disregarded important pieces of data thatare extremely relevant to patients and physicians. Mostsignificantly the editorials ignored data that showed no evidenceof any increase in cardiovascular death or death from anycause."...

NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien Tablets

FLEMINGTON, N.J.--(BUSINESS WIRE)--Jun 5, 2007 - NovaDel PharmaInc. (AMEX: NVD), a specialty pharmaceutical company developingoral spray formulations for a broad range of marketed treatments,today announced that its two clinical studies comparing zolpidemoral spray with zolpidem tablets have met their primarypharmacokinetic (PK), pharmacodynamic (PD) and safety objectives.Zolpidem tablets a...

CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine companyfocused on the development and commercialization ofmultifunctional, tumor-targeted therapies today presented a posterabstract at the 43rd American Society of Clinical Oncology (ASCO)Annual meeting. The poster, entitled "Preliminary Results of aPhase 1 Clinical Trial of CYT-6901," announced the preliminary dataof a National Ca...

Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference

- Phase I data from XL880, Phase II data from XL999 studiesscheduled for presentation during oral, poster sessions - SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --Exelixis, Inc. announced today that data from clinical trials ofthe company's investigational compounds XL880 and XL999 will bepresented at the 2007 American Society of Clinical Oncology AnnualMeeting (ASCO), which...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

KENILWORTH, N.J., May 18, 2007 /PRNewswire-FirstCall/ -- A totalof 20 oral and poster presentations on clinical studies withSchering-Plough's hepatitis products, including PEGINTRON(TM)(peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combinationtherapy for chronic hepatitis C virus (HCV) infection, as well asboceprevir (SCH 503034), the company's investigational oral HCVprotease i...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

Cytos Biotechnology reports positive results from placebocontrolled phase IIa study in patients suffering from house dustmite allergy SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos BiotechnologyAG (SWX:CYTN) reported today positive results from a multi-centreand placebo-controlled phase IIa study with different formulationsof CYT003-QbG10, an immunotherapeutic product can...

KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time

Research Breakthrough Will Aid in Developing Therapies to Preventand Reverse Atherosclerotic Heart Disease EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- KineMed, Inc.,a pathway-based drug discovery and development company, announcedtoday the first method for measuring the efflux of cholesterol fromtissues in animals through the pathway known as reverse cholesteroltransport (RCT). RCT i...

Ferring Reports on ENDOMETRIN Presentations at Pacific Coast Reproductive Society Annual Meeting

Progesterone Vaginal Supplement Studied in Largest-Ever IVF Trialin US RANCHO MIRAGE, Calif., April 18, 2007 /PRNewswire/ -- Results offour studies evaluating Ferring Pharmaceuticals' ENDOMETRIN(R), anovel progesterone vaginal insert in development for luteal phasesupport (supplementation to provide support for implantation andthe early stages of pregnancy) in assisted reproductivetechno...

Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C

Highlights key data at the 42nd annual meeting of the EuropeanAssociation for the Study of the Liver (EASL) KENILWORTH, N.J., April 11, 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation reaffirms its commitment to advancingthe science and treatment of chronic hepatitis C virus (HCV)infection with several key data presentations at the EuropeanAssociation for the Study of the Liver...

Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a seasonal influenza vaccineformulated with the company's Vaxfectin(TM) adjuvant generated upto 60-fold higher antibody responses than an unformulated vaccineat the same dose in a recently completed study in mice. Formulationof sanofi pasteur's Fluzone(R) commercial vaccine withVaxfectin(TM) al...

New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy

COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-FirstCall/ --Wyeth Pharmaceuticals, a division of Wyeth , provides comment on are- analysis of pooled data from both hormone therapy arms of theWomen's Health Initiative (WHI) Study published today in theJournal of the American Medical Association. The pooled analysisshowed no apparent increase in coronary heart disease for women whoinitiate...

Isotechnika's independent data monitoring committee conducts review of phase 2b kidney transplant trial

- Company Set to Host Evening Symposium at ATC - EDMONTON, March 27 /CNW/ - Isotechnika Inc. announced today thatan independent data monitoring committee (DMC) has met and reviewedthe interim data from the Phase 2b kidney transplant (PROMISE)trial. The review included 3 month data from approximately 1/3 ofthe anticipated 332 patients to be enrolled. The DMC hasrecommended that...

Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation announced today that results of thePhase II trial of its novel oral thrombin receptor antagonist (TRA)SCH 530348 will be presented at the 2007 annual Scientific Sessionsof the of Cardiology (ACC.07)/Innovation in Intervention (i2)Summit, March 24-27 in New Orleans. The Phase II trial, referred toas the...

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced that data from three completedPhase III multi- center clinical studies of ferumoxytol as anintravenous iron replacement therapeutic will be presented duringthe National Kidney Foundation (NKF) 2007 Spring Clinical Meetingstaking place April 10th through 14th in Orlando, Florida. Twoposters contai...